<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952912</url>
  </required_header>
  <id_info>
    <org_study_id>PKEP-OP</org_study_id>
    <nct_id>NCT01952912</nct_id>
  </id_info>
  <brief_title>Plasmakinetic Enucleation of the Prostate and Open Prostatectomy to Treat Large Prostates</brief_title>
  <official_title>Comparison of Plasmakinetic Enucleation of the Prostate With Open Prostatectomy for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that Plasmakinetic Enucleation of the Prostate (PkEP) might
      yield functional results comparable to OP but with lower perioperative morbidity, and have
      equivalent long-term efficacy with OP for large prostates. The first objective was to
      demonstrate the non-inferiority of PKEP compared to OP concerning Qmax at one year
      postoperatively.

      To explore the long-term efficacy, we compared the efficacy, safety, and morbidity of PkEP
      with those of OP in BPH patients with prostate glands larger than 100 g over a follow-up
      period of 6 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qmax at one year postoperatively</measure>
    <time_frame>1 year postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qmax at other time points after surgery</measure>
    <time_frame>1, 3, 6, 24, 36, 48, 60 and 72 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resected adenoma weight</measure>
    <time_frame>right after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>during the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>perioperatively and on the first postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative International Prostate Symptom Score</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48, 60 and 72 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of catheterization</measure>
    <time_frame>after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of postoperative hospital stay</measure>
    <time_frame>after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48, 60 and 72 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVR</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48, 60 and 72 months postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>PkEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PkEP</intervention_name>
    <arm_group_label>PkEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OP</intervention_name>
    <arm_group_label>OP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  •Qmax &lt; 12 mL/s, IPSS &gt;19

               -  Age between 50 and 70 years

               -  Prostate volume larger than 100 mL, as determined by TRUS post-void residual
                  urine volume greater than 50 ml medical therapy failure.

        Exclusion Criteria:

          -  •severe pulmonary disease or heart disease, coagulopathy, neurogenic bladder, bladder
             calculus, bladder cancer, prostate cancer, urethral stricture and previous prostate or
             urethral surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuzhou General Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

